Cognes
Cognes
Cognes develops patented facial biomarker technology to enable early detection and long-term monitoring of cognitive decline. Based in Stockholm, Sweden, the company builds research-focused AI that transforms short frontal smartphone videos into interpretable cognitive indicators for research, treatment development, and scalable screening.
What we do
We capture a brief frontal video via a standard smartphone, extract geometric and dynamic facial features with computer vision, and apply machine learning models to estimate cognitive indicators. Outputs are designed to support early identification of cognitive changes, accelerate clinical trial recruitment, and enable long-term monitoring of progression.
Collaborations & contact
Cognes works with an extensive research network (50+ partners) and is trusted by institutions including Massachusetts General Hospital, Harvard Medical School, University of Porto, TEF Health, PREDICTOM, Alzheimer's Foundations, and Brilliant Minds. The technology is covered by US and EU patents and targets a public launch in 2026. Contact: [email protected]. Location: Stockholm, Sweden.